FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAcrux Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
ACR.AX
Acrux Limited Stock AnalysisComprehensive stock analysis for Acrux Limited (ACR.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACR.AX
ACR.AX
Acrux Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
ACR.AX
  1. Home
  2. Stocks
  3. Acrux Limited

Acrux Limited

🇦🇺ACR.AX•ASX

Acrux Limited

🇦🇺ACR.AX•ASX

Your view on ACR.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Acrux Limited

Industry
Biotechnology
Sector
Healthcare
CEO
John Warmbrunn
Headquarters
103-113, Stanley Street, West Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
John Warmbrunn
Headquarters
103-113, Stanley Street, West Melbourne, VIC, AU
Description

Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets.

The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels.

Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Acrux Limited. Starting points for Acrux Limited: beta 0.99 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Acrux Limited. Acrux Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Acrux Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterJun 2017Next quarterJun 2018This yearYear to Jun 2017Next yearYear to Jun 2018
Average estimateAUD 0.03−AUD 0.06AUD 0.07AUD 0.09
Lowest estimateAUD 0.02−AUD 0.06AUD 0.07AUD 0.09
Highest estimateAUD 0.04−AUD 0.06AUD 0.07AUD 0.09
Number of analysts3332
A year ago————
Growth vs a year ago————

Revenue estimates

TotalThis quarterJun 2017Next quarterJun 2018This yearYear to Jun 2017Next yearYear to Jun 2018
Average estimateAUD 19.95MAUD 2.93MAUD 24.00MAUD 28.63M
Lowest estimateAUD 16.49MAUD 2.69MAUD 24.00MAUD 28.63M
Highest estimateAUD 22.76MAUD 3.06MAUD 24.00MAUD 28.63M
Number of analysts3343
A year ago————
Growth vs a year ago————

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Acrux Limited. Acrux Limited has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ACR.AX20 companies
Compare ACR.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
1AD.AXAdAlta LimitedHealthcareBiotechnology—
ANR.AXAnatara Lifesciences LtdHealthcareBiotechnology—
BGT.AXBio-Gene Technology LimitedBasic MaterialsAgricultural Inputs—
BIT.AXBiotron LimitedHealthcareBiotechnology—
GLH.AXGlobal Health LimitedHealthcareMedical - Care Facilities—
HIQ.AXHITIQ LimitedHealthcareMedical - Healthcare Information Services—
IBX.AXImagion Biosystems LimitedHealthcareMedical - Diagnostics & Research—
IVX.AXInvion LimitedHealthcareDrug Manufacturers - Specialty & Generic—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$41.0M
PLRZPolyrizon Ltd.HealthcareNASDAQ$12.4M
PLURPluri Inc.HealthcareNASDAQ$9.9M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$254.6M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$80.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$3.0M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.2M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$236,124
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Acrux Limited.

ACR.AX AnalysisWeak
Past
1
Growth
1
Health
3
Profit
1
Value
1